This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors. The following dosing schedule, consisting of 21-day treatment cycles, is being examined:
Five days on/two days off on Days 1 to 5, 8 to 12, and 15 to 19 (5/2 schedule).
